Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00989651 Phase I Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed USA 0
NCT01145430 Phase I Pegylated liposomal doxorubicin + Veliparib Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer Completed USA 0
NCT01239732 Phase III Bevacizumab + Carboplatin + Paclitaxel A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NLD | ITA | FRA | ESP | CAN | AUT 31
NCT01248962 Phase II Carboplatin Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer Completed USA 0
NCT01281514 Phase I Carboplatin + Everolimus + Pegylated liposomal doxorubicin Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed USA 0
NCT01504126 Phase I Propranolol Beta-Blocker / Ovarian Completed USA 0
NCT01519869 Phase I Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma Completed USA 0
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed USA | CAN 1
NCT01669798 Phase II Nintedanib BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer Completed USA 0
NCT01849874 Phase III Binimetinib A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Terminated USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 8
NCT01936974 Phase II Bevacizumab + Cisplatin + Gemcitabine Bevacizumab + Gemcitabine + Oxaliplatin Bevacizumab + Carboplatin + Gemcitabine Bevacizumab + Gemcitabine (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma Terminated USA 0
NCT01974765 Phase II Enzalutamide Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Completed USA 0
NCT02033616 Phase II Ovapuldencel-T Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas Unknown status USA 0
NCT02042430 Phase I Epacadostat INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT02059265 Phase II Dasatinib Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Terminated USA 0
NCT02101775 Phase II Gemcitabine Adavosertib + Gemcitabine Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA | CAN 1
NCT02121990 Phase I Bevacizumab + Cisplatin + Olaparib + Paclitaxel Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Completed USA 0
NCT02122185 Phase II Metformin Carboplatin + Docetaxel + Paclitaxel Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended USA 0
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed USA 0
NCT02166905 Phase Ib/II Poly ICLC Rasdegafusp alfa Epacadostat DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed USA 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02188550 Phase II Everolimus + Letrozole Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status USA 0
NCT02195973 Phase Ib/II Paclitaxel + Sonidegib Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer Completed USA 0
NCT02208375 Phase Ib/II Capivasertib + Olaparib Olaparib + Vistusertib mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Active, not recruiting USA 0
NCT02275039 Phase I MVAp53 Gemcitabine p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer Completed USA 0
NCT02283658 Phase II Everolimus + Letrozole Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed USA 0
NCT02316834 Phase I Talazoparib POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer Completed USA 0
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Terminated USA 0
NCT02431559 Phase Ib/II Aldoxorubicin + Durvalumab + Motolimod A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated Completed USA 1
NCT02440425 Phase II Paclitaxel Pembrolizumab Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer Completed USA 0
NCT02459301 Phase I Monalizumab Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin Completed CAN 0
NCT02470585 Phase III Carboplatin Paclitaxel Veliparib Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Terminated USA | NZL | GBR | ESP | AUS 6
NCT02485990 Phase Ib/II Olaparib Tremelimumab Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) Terminated USA 0
NCT02537444 Phase II Acalabrutinib Pembrolizumab ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191) Completed USA 0
NCT02571725 Phase Ib/II Olaparib + Tremelimumab PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer Active, not recruiting USA 0
NCT02608684 Phase II Cisplatin + Gemcitabine + Pembrolizumab A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer Completed USA 0
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU 1
NCT02657928 Phase II Letrozole + Ribociclib Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer Completed USA 0
NCT02659241 Phase I Adavosertib A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer Active, not recruiting USA 0
NCT02661815 Phase I Paclitaxel + Ricolinostat Bevacizumab A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Terminated USA 0
NCT02764333 Phase II Durvalumab + TPIV 200 TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer Completed USA 0
NCT02833506 Phase I NY-ESO-1 peptide vaccine + Sirolimus NY-ESO-1 peptide vaccine Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Withdrawn USA 0
NCT02834975 Phase II Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). Terminated USA 0
NCT02889900 Phase II Cediranib + Olaparib Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO) Completed USA 0
NCT02922764 Phase I RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting USA 0
NCT02953457 Phase II Durvalumab + Olaparib + Tremelimumab Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Active, not recruiting USA 0
NCT03017131 Phase I Aldesleukin + Cyclophosphamide + Decitabine + Letetresgene autoleucel Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 0
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Unknown status USA | BEL 0
NCT03029403 Phase II Cyclophosphamide + Maveropepimut-S + Pembrolizumab Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Active, not recruiting CAN 0
NCT03054298 Phase I HuCART-meso cells Cyclophosphamide CAR T Cells in Mesothelin Expressing Cancers Active, not recruiting USA 0
NCT03054909 Phase I Nogapendekin alfa inbakicept QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer Completed USA 0
NCT03206047 Phase Ib/II Atezolizumab + Guadecitabine Atezolizumab Atezolizumab + Guadecitabine + Rasdegafusp alfa Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT03206645 Phase I Carboplatin + Paclitaxel + PTC596 PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy Completed USA 0
NCT03246074 Phase I Fostamatinib + Paclitaxel Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer Active, not recruiting USA 0
NCT03394885 Phase Ib/II Atezolizumab + Carboplatin + Paclitaxel Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (AdORN) Completed USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03531645 Phase II Fulvestrant + Palbociclib Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma Active, not recruiting USA 0
NCT03596281 Phase I Pegylated liposomal doxorubicin + Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer (PEMBOV) Active, not recruiting FRA 0
NCT03598270 Phase III Carboplatin + Gemcitabine Niraparib Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Pegylated liposomal doxorubicin Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab + Niraparib Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) Active, not recruiting ITA | FRA | ESP | DEU | BEL 0
NCT03675893 Phase II Abemaciclib + LY3023414 Abemaciclib + Letrozole Abemaciclib + Letrozole + Metformin Abemaciclib + Letrozole + LY3023414 Abemaciclib + Letrozole + Zotatifin Abemaciclib + Letrozole +/- Metformin in Recurrent or Persistent Endometrial Cancer Recruiting USA 0
NCT03691376 Phase I Melphalan NY-ESO-1 TCR CD4- CD34+ HSC Aldesleukin Autologous NY-ESO-1-specific CD8-positive T cells Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT03735589 Phase Ib/II alphaDC1 + NK-like CTLs Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Withdrawn USA 0
NCT03839524 Phase I TG4050 A Trial Evaluating TG4050 in Ovarian Carcinoma. Active, not recruiting USA | FRA 0
NCT03924245 Phase Ib/II Entinostat Entinostat + Olaparib Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Terminated USA 0
NCT03959761 Phase Ib/II Nivolumab Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma (ICONIC) Unknown status FRA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04570839 Phase Ib/II BMS-986207 + COM701 + Nivolumab Nivolumab COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. Active, not recruiting USA 0
NCT04657068 Phase Ib/II ART0380 + Gemcitabine ART0380 Gemcitabine A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT04706962 Phase I TH1902 TH1902 in Patients With Advanced Solid Tumors Recruiting USA | CAN 0
NCT04787289 Phase II Bevacizumab A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer Recruiting CAN 0
NCT04861181 FDA approved Niraparib NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK) Recruiting FRA 0
NCT04918186 Phase II BA3021 + Durvalumab Durvalumab + Mecbotamab Vedotin Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC) Recruiting USA | CAN 0
NCT05116189 Phase III Bevacizumab + Docetaxel Bevacizumab + Paclitaxel + Pembrolizumab Bevacizumab + Docetaxel + Pembrolizumab Bevacizumab + Paclitaxel Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | DEU | CAN | BEL | AUS 15
NCT05257408 Phase III Nab-paclitaxel Nab-paclitaxel + Relacorilant Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 6
NCT05261490 Phase Ib/II Pegylated liposomal doxorubicin + TTI-622 Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer Terminated USA 0
NCT05358639 Phase I Navitoclax + Olaparib Combination of Olaparib and Navitoclax in Women With HGSC and TNBC Recruiting CAN 0
NCT05394675 Phase I DS-9606a A Study of DS-9606a in Patients With Advanced Solid Tumors Recruiting USA | GBR 0
NCT05465941 Phase II PLX038 PLX038 for the Treatment of Patients With Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Recruiting USA 0
NCT05564377 Phase II Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Recruiting USA 1
NCT05601700 Phase III Carboplatin + Paclitaxel Letrozole Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (LEPRE) Recruiting ITA 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP 2
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT06028932 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients Recruiting USA 0